Publications 2009
Ligand-Selective Photodissociation from [Ru(bpy)(4-aminopyridine)4]2+: a Spectroscopic and Computational Study
L. Salassa, C. Garino, G. Salassa, C. Nervi, R. Gobetto, C. Lamberti, D. Gianolio, R. Bizzarri, P.J. Sadler
Inorg. Chem. 2009, 48, 1469-1481
Photoinduced reactions of cis,trans,cis-[PtIV(N3)2(OH)2(NH3)2] with 1-methylimidazole
H. I. A. Phillips, L. Ronconi, and P. J. Sadler
Chem. Eur. J. 2009, 15, 1588-1596
Metal ion-nucleic acid interactions in disease and medicine
A.M. Pizarro and P. J. Sadler
Chapter 10 in Nucleic Acid-Metal Ion Interactions (2009), N. Hudd (Ed.), Royal Society of Chemistry, 350-416
Photoactive trans ammine/amine diazido platinum(IV) complexes
F. S. Mackay, S. A. Moggach, A. Collins, S. Parsons and P. J. Sadler
Inorg. Chim. Acta 2009, 362, 811-819 (Special issue for B. Lippert)
Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives
S. H. van Rijt, A. F. A. Peacock, R. D. L. Johnstone, S. Parsons and P. J. Sadler
Inorg. Chem. 2009, 48, 1753-1762
Precious anticancer drugs
P. J. Sadler
Chemistry & Industry, 23 Feb 2009, pp 18-20
Organometallic Osmium(II) and Ruthenium(II) Biphenyl Sandwich Complexes: X-ray Crystal Structures and 187Os NMR Studies in Solution
J. C. Gray, A. Pagelot, A. Collins, F. P. A. Fabbiani, S. Parsons and P. J. Sadler
Eur. J. Inorg. Chem. 2009, 2673-2677
Unusual DNA binding modes for metal anticancer complexes
A. M. Pizarro and P. J. Sadler
Biochimie 2009, 91, 1198-1211
Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes
W. Hu, Q. Luo, X. Ma, K. Wu, J. Liu, Y. Chen, S. Xiong, J. Wang, P. J. Sadler and F. Wang
Chem. Eur. J. 2009, 15, 6586-6594
Isomer Separation and Gas-Phase Configurations of Organoruthenium Anticancer Complexes: Ion Mobility Spectrometry and Modeling
J. P. Williams, T. Bugarcic, A. Habtemariam, K. Giles, I. Campuzano, P. M. Rodger and P. J. Sadler
J. Am. Soc. Mass Spec. 2009, 20, 1119-1122
Insights into how nucleotide-binding domains power ABC transport
S. Newstead, P. W. Fowler, P. Bilton, E. P. Carpente, P. J. Sadler, D. J. Campopiano, M. S. P. Sansom and S. Iwata
Structure 2009, 17, 1213-1222
Controlling platinum, ruthenium and osmium reactivity for anticancer drug design
P. C. A. Bruijnincx and P. J. Sadler
Adv. Inorg. Chem. 2009, 61, 1-62
Plasma fatty acid levels may regulate the Zn2+-dependent activities of histidine-rich glycoprotein
A. J. Stewart, C. A. Blindauer and P. J. Sadler
Biochimie 2009, 91, 1518-1522
Decomposition pathways for the photoactivated anticancer complex cis,trans,cis-[Pt(N3)2(OH)2(NH3)2]: insights from DFT calculations
L. Salassa, H.I.A. Phillips and P. J. Sadler
Phys. Chem. Chem. Phys. 2009, 11, 10311-10316
Structure, properties, and engineering of the major zinc binding site on human albumin
C. A. Blindauer, I. Harvey, K. E. Bunyan, A. J. Stewart, D. Sleep, D. J. Harrison, S. Berezenko, and P. J. Sadler
J. Biol. Chem. 2009, 284, 23116-23124
Ruthenium(II) arene anticancer complexes with redox-active diamine ligands
T. Bugarcic, A. Habtemariam, R. J. Deeth, F. P. A. Fabbiani, S. Parsons and P. J. Sadler
Inorg. Chem. 2009, 48, 9444–9 453
Influence of oxygenation on the reactivity of ruthenium-thiolato bonds in arene anticancer complexes: insights from XAS and DFT
T. Sriskandakumar, H. Petzold, P. C. A. Bruijnincx, A. Habtemariam, P. J. Sadler and P. Kennepohl
J. Am. Chem. Soc. 2009, 131, 13355-13361
Identification by NMR Spectroscopy of the Two Stereoisomers of the Platinum Complex [PtCl2(S-ahaz)] (S-ahaz = 3(S)-aminohexahydroazepine) Bound to a DNA 14-mer oligonucleotide. NMR Evidence of Structural Alteration of a Platinated A·T-rich 14-mer DNA Duplex
C. I. Diakos, B. A. Messerle, P. del S. Murdoch, J. A. Parkinson, P. J. Sadler, R. R. Fenton and T. W. Hambley
Inorg. Chem., 2009, 48, 3047-3056
Photocontrolled nucleobase binding to an organometallic RuII arene complex
S. Betanzos-Lara, L. Salassa, A. Habtemariam and Peter J. Sadler
Chem. Commun. 2009, 6622 – 6624
Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes
S. H. van Rijt, A. J. Hebden, T. Amarasekera, R. J. Deeth, G. J. Clarkson, S. Parsons, P. C. McGowan and P. J. Sadler
J. Med. Chem. 2009, 52, 7753-7764
Use of ion mobility mass spectrometry and a collision cross-section algorithm to study an organometallic ruthenium anticancer complex and its adducts with a DNA oligonucleotide
J. P. Williams, J. A. Lough, I. Campuzano, K. Richardson and P. J. Sadler
Rapid. Commun. Mass Spectrom. 2009, 23, 3563-3569
In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary carcinoma model
A. Bergamo, A. Masi, A. F. A. Peacock, A. Habtemariam, P. J. Sadler, G. Sava
J. Inorg. Biochem. 2009, 104, 79-86
Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs
S. H. van Rijt and P. J. Sadler
Drug Discovery Today, 2009, 14, 1089-1097
Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine
N. J. Farrer, L. Salassa and P. J. Sadler
Dalton Trans. 2009, 10690-10701